Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

66.26 +0.29 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,043,353
Open 65.45
Bid (Size) 66.16 (1)
Ask (Size) 67.28 (1)
Prev. Close 65.97
Today's Range 65.35 - 66.68
52wk Range 61.15 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Despite its growth, NASDAQ:BMRN remains within the realm of affordability. 
Via Chartmill

Performance

YTD
-32.42%
-32.42%
1 Month
+0.20%
+0.20%
3 Month
-21.47%
-21.47%
6 Month
-21.34%
-21.34%
1 Year
-32.74%
-32.74%

More News

Read More
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
Via MarketBeat
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
Via Benzinga
NASDAQ:BMRN stands out as a growth opportunity that won't break the bank.
Via Chartmill
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
Via Benzinga
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
Via Benzinga
CAMP4 Analyst Highlights Rare Disease Platform Potential
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
Via Benzinga
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
From Monopar Therapeutics Inc.
Via GlobeNewswire
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
How Is The Market Feeling About Biomarin Pharmaceutical?
Via Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Via Benzinga
NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
3 Oversold Stocks with Big RSI Rebound Potential
Via MarketBeat
Topics Economy
Exposures Interest Rates
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Via Chartmill
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
Via Benzinga
Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents.
Via Chartmill
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.